Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity

Cover Page
  • Authors: Nasonov E.L.1,2, Reshetnyak T.M.1,3, Alekberova Z.S.1
  • Affiliations:
    1. ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
    2. ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
    3. ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
  • Issue: Vol 92, No 5 (2020)
  • Pages: 4-14
  • Section: Editorial
  • URL:
  • DOI:
  • Cite item


Uncontrolled hypercoagulation and inflammation (“thromboinflammation”), which are both independent and closely related and amplifying each other pathological processes, form the basis for pathogenesis of a wide range of diseases and complications, including immuno-inflammatory (autoimmune) rheumatic diseases, with the development of potentially fatal injuries of internal organs. Thrombotic microangiopathy is one of the most prominent prototypes of “thromboinflammatory” pathological conditions. The close link between environmental factors, hemostasis genetic defects and the complement system, inflammation and autoimmunity as pathogenetic mechanisms of microthrombosis draws particular attention to studying thrombotic microangiopathy in immuno-inflammatory rheumatic diseases, primarily systemic lupus erythematosus, antiphospholipid syndrome and scleroderma renal crisis. In future, these studies may be important for expanding the idea of the role of autoimmune mechanisms in pathogenesis of “critical” hemostasis disorders in human diseases, and for developing new approaches to therapy. Recently, special attention has been paid to the treatment of systemic lupus erythematosus and antiphospholipid syndrome with eculizumab, which is humanized monoclonal IgG2/4k antibody that blocks the complement component C5a and the membrane attack complex (C5b-9) formation, and which is registered for the treatment of atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, as well as severe forms of myasthenia gravis and neuromyelitis optica. Further studies in this direction will create prerequisites for improving the prognosis not only in patients with orphan disorders, but also for widespread human diseases.

Full Text

Restricted Access

About the authors

Evgeny L. Nasonov

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)

Author for correspondence.
ORCID iD: 0000-0002-1598-8360

Russian Federation, Москва

акад. РАН, д.м.н., проф., науч. рук., проф.

Tatyana M. Reshetnyak

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России

ORCID iD: 0000-0003-3552-2522

Russian Federation, Москва

д.м.н., рук. лаб. сосудистой ревматологии, проф. каф. ревматологии

Zemfira S. Alekberova

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»

ORCID iD: 0000-0002-6619-718X

Russian Federation, Москва

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»


  1. Herwald H, Theopold U. Hemostasis in invertebrates and vertebrates: an evolutionary excursion. J Innate Immun. 2011;3(1):1-2. doi: 10.1159/000322064
  2. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-18. doi: 10.1182/blood-2018-11-882993
  3. Chanchal S, Mishra A, Singh MK, Ashraf MZ. Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes. Front Cell Dev Biol. 2020;8:73. doi: 10.3389/fcell.2020.00073
  4. Margetic S. Inflammation and haemostasis. Biochem Med. 2012;22:49-62. doi: 10.11613/BM.2012.006
  5. Babar F, Cohen SD. Thrombotic Microangiopathies with Rheumatologic Involvement. Rheum Dis Clin North Am. 2018 Nov;44(4):635-49. doi: 10.1016/j.rdc.2018.06.010
  6. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654-66. doi: 10.1056/NEJMoa1410490
  7. Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am. 2017;101(2):395-415. doi: 10.1016/j.mcna.2016.09.010
  8. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2):300-17. doi: 10.2215/CJN.00620117
  9. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. 2019;12(3):333-7. doi: 10.1093/ckj/sfz040
  10. Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4-21. doi: 10.1111/1744-9987.12763
  11. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;38:817-24. doi: 10.1016/S0140-6736(17)30062-4
  12. Plautz WE, Raval JS, Dyer MR, et al. ADAMTS13: origins, applications, and prospects. Transfusion. 2018;58(10):2453-62. doi: 10.1111/trf.14804
  13. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne’s Thread Into the Labyrinth of Complement Therapeutics. Front Immunol. 2019;10:337. doi: 10.3389/fimmu.2019.00337
  14. Kotzen ES, Roy S, Jain K. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-86. doi: 10.1053/j.ackd.2019.08.012
  15. Chaturvedi S, Brodsky RA, McCrae KR. Complement in the Pathophysiology of the Antiphospholipid Syndrome. Front Immunol. 2019;10:449. doi: 10.3389/fimmu.2019.00449
  16. Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018;17(9):882-9. doi: 10.1016/ j.autrev.2018.03.012
  17. Allanore Y, Distler O, Matucci-Cerinic M, Denton CP. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis Rheumatol. 2018;70(2):162-70. doi: 10.1002/art.40377
  18. Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538-47. doi: 10.1038/nrrheum.2017.125
  19. Goldberg BS, Ackerman ME. Antibody-mediated complement activation in pathology and protection. Immunol Cell Biol. 2020 Mar 6. doi: 10.1111/imcb.12324
  20. Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA. Complement activation and regulation in rheumatic disease. Semin Immunol. 2019;45:101339. doi: 10.1016/j.smim.2019.101339
  21. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol. 2019;10:672. doi: 10.3389/fimmu.2019. 00672
  22. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
  23. Насонов Е.Л. Системная красная волчанка. В кн.: Российские клинические рекомендации. 2017. М.: ГЭОТАР-Медиа, 2017; с. 113-41 [Nasonov EL. Systemic lupus erythematosus. In: Russian Kliscientific recommendations. 2017. Moscow: GEOTAR-Media, 2017; p. 113-41 (In Russ.)].
  24. Couture P, Hie M, Pineton de Chambrun M, et al. FRI0302 Systemic lupus erythematosus-associated thrombotic microangiopathies in 60 patients: clinical features, prognosis and treatment in a french multicentric cohort. Ann Rheum Dis. 2018;77:688-9.
  25. Yue C, Su J, Gao R, et al. Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles. J Rheumatol. 2018;45(11):1549-56. doi: 10.3899/jrheum.170811
  26. Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005
  27. Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol. 1992;19:1474-8. PMid: 1433020.
  28. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol. 1991;18:1916-8. PMid: 1795331.
  29. Tulai IM, Penciu OM, Raut R, Rudinskaya A. Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. Tex Heart Inst J. 2019;46(1):48-52. doi: 10.14503/THIJ-17-6472
  30. Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10:279-89. doi: 10.1038/nrneph.2014.38
  31. Tsuchimoto A, Matsukuma Y, Ueki K, et al. Thrombotic microangiopathy associated with anticardiolipin antibody in a kidney transplant recipient with polycythemia. CEN Case Rep. 2019;8(1):1-7. doi: 10.1007/s13730-018-0354-x
  32. Zhou XJ, Chen M, Wang SX, et al. A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report. Lupus. 2017;26(7):777-82. doi: 10.1177/0961203316682098
  33. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-6. doi: 10.1136/ard.2003.007245
  34. Asherson RA, Pierangel SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66:429-33. doi: 10.1136/ard.2006.067033
  35. Myakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295-306. doi: 10.1111/j.1538-7836.2006.01753.x
  36. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27. doi: 10.1002/art.10187
  37. Решетняк Т.М., Алекберова З.С., Александрова Е.Н. и др. Клинические аспекты антифосфолипидного синдрома. Вестн. РАМН. 2003;7:31-4 [Reshetnyak TM, Alekberova ZS, Alexandrova EN, et al. Clinic-clinical aspects of antiphospholipid syndrome. Vestn. RAMS. 2003;7:31-4 (In Russ.)].
  38. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004 [Nasonov EL. Antifosfolipidnyi sindrom. Moscow: Litterra, 2004 (In Russ.)].
  39. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378(21):2010-21. doi: 10.1056/ NEJMra1705454
  40. Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-4. doi: 10.1182/bloodadvances.2018019596
  41. Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Ren Fail. 2019;42(1):19-29. doi: 10.1080/0886022X.2019.1702057
  42. Ono M, Ohashi N, Namikawa A, et al. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. Intern Med. 2018;57(11):1617-23. doi: 10.2169/internalmedicine.0228-17
  43. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483-95. doi: 10.1038/nrneph.2017.85
  44. Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi: 10.1186/ar4142
  45. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, et al; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013;42(4):417-23. doi: 10.1016/j.semarthrit.2012.05.005
  46. Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018;92:1-11. doi: 10.1016/j.jaut.2018.05.007
  47. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304. doi: 10.1136/annrheumdis-2019-215213
  48. Насонов Е.Л., Бекетова Т.В., Ананьева Л.П. и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40 [Nasonov ЕL, Beketova TV, Ananyeva LP, et al. Prospects for anti-b-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (In Russ.)]. doi: 10.14412/1995-4484-2019-3-40
  49. Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085-90. doi: 10.1016/j.autrev.2013.05.004
  50. Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015 Feb;7(1):26-30. doi: 10.1177/1759720X14554793
  51. Wang CR, Weng CT, Liu MF. Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. Semin Arthritis Rheum. 2017;47(1):e7-e8. doi: 10.1016/j.semarthrit.2017.03.012
  52. Diószegi Á, Tarr T, Nagy-Vincze M, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018;27(9):1552-8. doi: 10.1177/0961203318768890
  53. Bhat SP, Rahman SZ. Rituximab treatment in new and refractory thrombotic thrombocytopenic purpura (TTP) patients: a review. IJMSCR. 2016;2:1-6.
  54. Sun L, Mack J, Li A, et al. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3(9):1512-8. doi: 10.1182/bloodadvances
  55. Coppo P. Cuker A, George JN. Thrombotic thrombocytopenic purputa: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019;3:26-37. doi: 10.1002/rth2.12160
  56. Wijnsma KL, Ter Heine R, Moes DJAR, et al. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet. 2019;58(7):859-74. doi: 10.1007/s40262-019-00742-8
  57. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25-40. doi: 10.3904/kjim.201
  58. Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020;410:116648. doi: 10.1016/j.jns.2019.11
  59. Patel A, Lynch F, Shepherd SA. Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. Curr Treat Options Neurol. 2020;22(3):7. doi: 10.1007/s11940-020-0616-8
  60. Tinti MG, Carnevale V, Inglese M, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019;19(3):281-8. doi: 10.1007/s10238-019-00565-8
  61. De Holanda MI, Pôrto LC, Wagner T, et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36(12):2859-67. doi: 10.1007/s10067-017-3823-2
  62. Raufi AG, Scott S, Darwish O, et al. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep. 2016;8(3):6625. eCollection 2016 Sep 28.
  63. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2014;65(1):127-30. doi: 10.1053/j.ajkd.2014.07.031
  64. Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54(12):2286-8. doi: 10.1093/rheumatology/kev307
  65. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719-23. doi: 10.1002/art.34440
  66. Appenzeller S, Souza FH, Wagner Silva de Souza A, et al. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517-23. doi: 10.1016/j.semarthrit.2011.05.007
  67. Muller-Calleja N, Ritter S, Hollerbach A, et al. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv. 2018;2:979-86. doi: 10.1182/bloodadvances.2018017095
  68. Strakhan M, Hurtado-Sbordoni M, Galeas N, et al. 36-Year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014;2014:704371. doi: 10.1155/2014/704371
  69. Wig S, Chan M, Thachil J, et al. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2016;55:382-4. doi: 10.1093/rheumatology/kev371
  70. Gustavsen A, Skattum L, Bergseth G, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report. Medicine. 2017;96:e6338. doi: 10.1097/MD.0000000000006338
  71. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost. 2016;14:675-84. doi: 10.1111/jth.13257
  72. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014;93:e143. doi: 10.1097/MD.0000000000000143
  73. Barratt-Due A, Fløisand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016;55:1337-9. doi: 10.1093/rheumatology/kew040
  74. Guillot M, Rafat C, Buob D, et al. Eculizumab for catastrophic antiphospholipid syndrome – a case report and literature review. Rheumatology. 2018;57:2055-7. doi: 10.1093/rheumatology/key2
  75. Geethakumari PR, Mille P, Gulati R, Nagalla S. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfus Apher Sci. 2017;56(3):400-3. doi: 10.1016/j.transci.2017.02.007
  76. Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. Clin Rheumatol. 2015;21(6):311-3. doi: 10.1097/RHU.0000000000000290
  77. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14(2):459-65. doi: 10.1111/ajt.12540
  78. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362(18):1744-5. doi: 10.1056/NEJMc0910965
  79. Bakhtar O, Thajudeen B, Braunhut BL, et al. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation. 2014;98(3):e17-8. doi: 10.1097/TP.0000000000000267
  80. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13(8):2179-85. doi: 10.1111/ajt.12319
  81. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x
  82. Olson SR, Lu E, Sulpizio E, et al. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol. 2018;48(2):96-107. doi: 10.1159/000492033
  83. Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341-52. doi: 10.1016/j.molimm.2019.07.030
  84. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol. 2019 Apr 3;10:672. doi: 10.3389/fimmu.2019.00672
  85. Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoS One 11:e0164646. doi: 10.1371/journal.pone.0164646
  86. Jayne DRW, Bruchfeld AN, Harper L, et al; CLEAR Study Group. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017;28(9):2756-67. doi: 10.1681/ASN.2016111179
  87. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012;120:3603-10. doi: 10.1182/blood-2012-04-420943
  88. Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020;11:2040620720902904. doi: 10.1177/2040620720902904



Abstract - 68

PDF (Russian) - 37





  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies